CRISPR mediated HeLa cells--front fighter of medical breakthroughs

 
GUANGZHOU, China - Dec. 10, 2020 - PRLog -- In 1952, Henrietta Lack (HeLa) cells became the first human cell line that could grow and divide endlessly in a laboratory, leading scientists to label these cells "immortal". Researchers originally took HeLa cells from an aggressive cervical cancer tumor. Researchers choose HeLa cell as a tool for multidisciplinary studies due to its immortal cell characteristics, available multi-omics database (genomic, proteomic, and transcriptomic), and easy to access these databases to design and modify research projects.

Application:
1. CRISPR/Cas9 mediated TERT disruption can suppress tumor cell survival
2. CRISPR/Cas9 introduces pathogenic MSH2 point mutations cause differential genomic de-stabilization in human cells
3. Reversible cloaking/uncloaking strategy with sgRNAs to control the CRISPR–Cas9 gene editing efficiency in vitro and in living cells

Gene editing in HeLa cell line possible to generate single or multiple gene knockouts, correct mutations, or insert reporter transgenes. These genomes edited HeLa cell lines will allow investigators to study cancer research, cancer therapeutics, cell death research, functional genomics, signaling pathways, drug discovery, drug response, and cell therapy.

Full article at https://www.ubigene.us/application/2969.html

Now our big promotion expires soon on 2020/12/10. Get your gene-edited cell lines shortly!
https://www.ubigene.us/activity/2964.html


Contact
Ubigene Biosciences
***@ubigene.com
+86-153 6067 3248
End
Email:***@ubigene.com
Posted By:***@ubigene.com Email Verified
Tags:CRISPR
Industry:Biotech
Location:Guangzhou - Guangdong - China
Subject:Reports
Account Email Address Verified     Disclaimer     Report Abuse
Ubigene Biosciences News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share